{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T18:33:37Z","timestamp":1792002817966,"version":"4.4.0"},"reference-count":30,"publisher":"BMJ","issue":"14","funder":[{"DOI":"10.13039\/501100003329","name":"Ministerio de Economa y Competitividad","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003329","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Heart"],"accepted":{"date-parts":[[2017,1,12]]},"published-print":{"date-parts":[[2017,7]]},"abstract":"<jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Cost-sharing scheme for pharmaceuticals in Spain changed in July 2012. Our aim was to assess the impact of this change on adherence to essential medication in patients with acute coronary syndrome (ACS) in the region of Valencia.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Population-based retrospective cohort of 10\u2009563 patients discharged alive after an ACS in 2009\u20132011. We examined a control group (low-income working population) that did not change their coinsurance status, and two intervention groups: pensioners who moved from full coverage to 10% coinsurance and middle-income to high-income working population, for whom coinsurance rose from 40% to 50% or 60%. Weekly adherence rates measured from the date of the first prescription. Days with available medication were estimated by linking prescribed and filled medications during the follow-up period.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Cost-sharing change made no significant differences in adherence between intervention and control groups for essential medications with low price and low patient maximum coinsurance, such as antiplatelet and beta-blockers. For costlier ACE inhibitor or an angiotensin II receptor blocker (ACEI\/ARB) and statins, it had an immediate effect in the proportion of adherence in the pensioner group as compared with the control group (6.8% and 8.3%\u2009decrease of adherence, respectively, p&lt;0.01 for both). Adherence to statins decreased for the middle-income to high-income group as compared with the control group (7.8% increase of non-adherence, p&lt;0.01). These effects seemed temporary.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Coinsurance changes may lead to decreased adherence to proven, effective therapies, especially for higher priced agents with higher patient cost share. Consideration should be given to fully exempt high-risk patients from drug cost sharing.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/heartjnl-2016-310610","type":"journal-article","created":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T20:20:23Z","timestamp":1488399623000},"page":"1082-1088","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":38,"title":["Effect of cost sharing on adherence to evidence-based medications in patients with acute coronary syndrome"],"prefix":"10.1136","volume":"103","author":[{"given":"Beatriz","family":"Gonz\u00e1lez L\u00f3pez-Valc\u00e1rcel","sequence":"first","affiliation":[{"name":"Department of Quantitative Methods in Economics and Management, University of Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juli\u00e1n","family":"Librero","sequence":"additional","affiliation":[{"name":"Health Services Research Unit, Center for Public Health Research (CSISP-FISABIO), Valencia, Spain"},{"name":"Red de Investigaci\u00f3n en Servicios de Salud en Enfermedades Cr\u00f3nicas (REDISSEC), Valencia, Spain"},{"name":"Navarrabiomed Biomedical Research Centre, Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"An\u00edbal","family":"Garc\u00eda-Sempere","sequence":"additional","affiliation":[{"name":"Health Services Research Unit, Center for Public Health Research (CSISP-FISABIO), Valencia, Spain"},{"name":"Red de Investigaci\u00f3n en Servicios de Salud en Enfermedades Cr\u00f3nicas (REDISSEC), Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luz Mar\u00eda","family":"Pe\u00f1a","sequence":"additional","affiliation":[{"name":"Centre for Research in Health and Economics (CRES), Pompeu Fabra University, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sof\u00eda","family":"Bauer","sequence":"additional","affiliation":[{"name":"Health Services Research Unit, Center for Public Health Research (CSISP-FISABIO), Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaume","family":"Puig-Junoy","sequence":"additional","affiliation":[{"name":"Centre for Research in Health and Economics (CRES), Pompeu Fabra University, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Oliva","sequence":"additional","affiliation":[{"name":"Department of Economic Analysis, University of Castilla-La Mancha, Toledo, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvador","family":"Peir\u00f3","sequence":"additional","affiliation":[{"name":"Health Services Research Unit, Center for Public Health Research (CSISP-FISABIO), Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Sanf\u00e9lix-Gimeno","sequence":"additional","affiliation":[{"name":"Health Services Research Unit, Center for Public Health Research (CSISP-FISABIO), Valencia, Spain"},{"name":"Red de Investigaci\u00f3n en Servicios de Salud en Enfermedades Cr\u00f3nicas (REDISSEC), Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2017,3,1]]},"reference":[{"key":"2025100704091812000_103.14.1082.1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2010.580"},{"key":"2025100704091812000_103.14.1082.2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.107.706820"},{"key":"2025100704091812000_103.14.1082.3","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1671"},{"key":"2025100704091812000_103.14.1082.4","first-page":"247","article-title":"Adherence to evidence-based therapies after acute coronary syndrome: a retrospective population-based cohort study linking hospital, outpatient, and pharmacy health information systems in Valencia, Spain","volume":"19","author":"Sanf\u00e9lix-Gimeno","year":"2013","journal-title":"J Manag Care Pharm"},{"key":"2025100704091812000_103.14.1082.5","doi-asserted-by":"publisher","DOI":"10.1001\/jama.297.2.177"},{"key":"2025100704091812000_103.14.1082.6","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.166.17.1842"},{"key":"2025100704091812000_103.14.1082.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra050100"},{"key":"2025100704091812000_103.14.1082.8","first-page":"45","article-title":"How patient cost-sharing trends affect adherence and outcomes: a literature review","volume":"37","author":"Eaddy","year":"2012","journal-title":"P T"},{"key":"2025100704091812000_103.14.1082.9","doi-asserted-by":"crossref","first-page":"357.e7","DOI":"10.1016\/j.amjmed.2012.09.004","article-title":"The impact of medication adherence on coronary artery disease costs and outcomes: a systematic review","volume":"126","author":"Bitton","year":"2013","journal-title":"Am J Med"},{"key":"2025100704091812000_103.14.1082.10","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0064914","article-title":"The effect of copayments for prescriptions on adherence to prescription medicines in publicly insured populations; a systematic review and meta-analysis","volume":"8","author":"Sinnott","year":"2013","journal-title":"PLoS One"},{"key":"2025100704091812000_103.14.1082.11","article-title":"Pharmaceutical policies: effects of cap and co-payment on rational use of medicines","volume":"5","author":"Luiza","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"2025100704091812000_103.14.1082.12","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1377\/hlthaff.2010.0336","article-title":"At Pitney Bowes, value-based insurance design cut copayments and increased drug adherence","volume":"29","author":"Choudhry","year":"2010","journal-title":"Health Aff (mildwood)"},{"key":"2025100704091812000_103.14.1082.13","unstructured":"Gibson TB , Mark TL , Axelsen K , et al . Impact of statin copayments on adherence and medical care utilization and expenditures. Am J Manag Care 2006:lSP11\u201319."},{"key":"2025100704091812000_103.14.1082.14","first-page":"509","article-title":"The effects of prescription drug copayments on statin adherence","volume":"12","author":"Gibson","year":"2006","journal-title":"Am J Manag Care"},{"key":"2025100704091812000_103.14.1082.15","doi-asserted-by":"publisher","DOI":"10.1001\/jama.298.1.61"},{"key":"2025100704091812000_103.14.1082.16","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.healthpol.2015.01.003","article-title":"The effects of reduced copayments on discontinuation and adherence failure to statin medication in Australia","volume":"119","author":"Knott","year":"2015","journal-title":"Health Policy"},{"key":"2025100704091812000_103.14.1082.17","unstructured":"Wooldridge JM . Econometric analysis of cross section and panel data. USA: BMJ Publishing Group, 2010."},{"key":"2025100704091812000_103.14.1082.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2013.09.014"},{"key":"2025100704091812000_103.14.1082.19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsa1107913"},{"key":"2025100704091812000_103.14.1082.20","first-page":"445","article-title":"Adherence to beta-blocker therapy under drug cost-sharing in patients with and without acute myocardial infarction","volume":"13","author":"Schneeweiss","year":"2007","journal-title":"Am J Manag Care"},{"key":"2025100704091812000_103.14.1082.21","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.106.665992"},{"key":"2025100704091812000_103.14.1082.22","doi-asserted-by":"publisher","DOI":"10.1257\/jep.7.3.135"},{"key":"2025100704091812000_103.14.1082.23","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(96)00268-5"},{"key":"2025100704091812000_103.14.1082.24","doi-asserted-by":"publisher","DOI":"10.1097\/01.mlr.0000207817.32496.cb"},{"key":"2025100704091812000_103.14.1082.25","first-page":"1","article-title":"Impact of the pharmaceutical copayment reform on the use of antidiabetics, Antithrombotics and for Chronic Obstructive Airway Disease Agents, Spain","volume":"90","author":"Puig-Junoy","year":"2016","journal-title":"Rev Esp Salud Publica"},{"key":"2025100704091812000_103.14.1082.26","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.16153"},{"key":"2025100704091812000_103.14.1082.27","doi-asserted-by":"crossref","first-page":"w195","DOI":"10.1377\/hlthaff.26.2.w195","article-title":"Value-based insurance design","volume":"26","author":"Chernew","year":"2007","journal-title":"Health Aff (Mildwood)"},{"key":"2025100704091812000_103.14.1082.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2012.06.050"},{"key":"2025100704091812000_103.14.1082.29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000234"},{"key":"2025100704091812000_103.14.1082.30","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/eht295"}],"container-title":["Heart"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/heartjnl-2016-310610","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T11:09:29Z","timestamp":1759835369000},"score":1,"resource":{"primary":{"URL":"https:\/\/heart.bmj.com\/lookup\/doi\/10.1136\/heartjnl-2016-310610"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,1]]},"references-count":30,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2017,6,26]]},"published-print":{"date-parts":[[2017,7]]}},"alternative-id":["10.1136\/heartjnl-2016-310610"],"URL":"https:\/\/doi.org\/10.1136\/heartjnl-2016-310610","relation":{},"ISSN":["1355-6037","1468-201X"],"issn-type":[{"value":"1355-6037","type":"print"},{"value":"1468-201X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,1]]}}}